Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (101-110 of 160) with videos related to

Pageof 16
Sort By:
HIV Medicine|October 30, 2020
Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected childrenR Freguja, A Bamford, M Zanchetta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancyRegis Kreitchmann, Brookie M Best, Jiajia Wang, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2024
Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation studyAdrie Bekker, Edmund V Capparelli, Mark Mirochnick, et al.
British Journal of Clinical Pharmacology|January 12, 2013
Reduced indinavir exposure during pregnancyTim R Cressey, Brookie M Best, Jullapong Achalapong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 11, 2017
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for NeonatesTim R Cressey, Baralee Punyawudho, Sophie Le Coeur, et al.
Epidemiology (Cambridge, Mass.)|July 13, 1999
The health effects of swimming in ocean water contaminated by storm drain runoffR W Haile, J S Witte, M Gold, et al.
The Lancet. HIV|September 10, 2019
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 listMartina Penazzato, Claire L Townsend, Natella Rakhmanina, et al.
Open Forum Infectious Diseases|July 21, 2021
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care TestingKelly A Johnson, Xin Niu, David V Glidden, et al.
Antiviral Therapy|December 14, 2011
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected childrenKulkanya Chokephaibulkit, Tim R Cressey, Edmund Capparelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2015
Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral TherapyRapeepan Suaysod, Nicole Ngo-Giang-Huong, Nicolas Salvadori, et al.
Pageof 16

Showing results (101-110 of 160) with videos related to

Sort By:
Pageof 16
HIV Medicine|October 30, 2020
Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected childrenR Freguja, A Bamford, M Zanchetta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 9, 2013
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancyRegis Kreitchmann, Brookie M Best, Jiajia Wang, et al.
The Journal of Antimicrobial Chemotherapy|August 2, 2024
Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation studyAdrie Bekker, Edmund V Capparelli, Mark Mirochnick, et al.
British Journal of Clinical Pharmacology|January 12, 2013
Reduced indinavir exposure during pregnancyTim R Cressey, Brookie M Best, Jullapong Achalapong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 11, 2017
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for NeonatesTim R Cressey, Baralee Punyawudho, Sophie Le Coeur, et al.
Epidemiology (Cambridge, Mass.)|July 13, 1999
The health effects of swimming in ocean water contaminated by storm drain runoffR W Haile, J S Witte, M Gold, et al.
The Lancet. HIV|September 10, 2019
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 listMartina Penazzato, Claire L Townsend, Natella Rakhmanina, et al.
Open Forum Infectious Diseases|July 21, 2021
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care TestingKelly A Johnson, Xin Niu, David V Glidden, et al.
Antiviral Therapy|December 14, 2011
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected childrenKulkanya Chokephaibulkit, Tim R Cressey, Edmund Capparelli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 4, 2015
Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral TherapyRapeepan Suaysod, Nicole Ngo-Giang-Huong, Nicolas Salvadori, et al.
Pageof 16